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Abstract  
The classic chronic myeloproliferative neoplasms (MPN) include different entities that pose 
significant challenges for their optimal diagnosis, treatment and overall management. 
Polycythemia Vera and Essential Thrombocythemia are the most common among chronic 
myeloproliferative neoplasms (MPNs); major causes of morbidity and mortality are 
represented by arterial and venous thrombosis, as well as evolution to myelofibrosis or 
transformation to acute leukemia. However, survival is only minimally affected. Therapy 
aims at reducing the rate of thrombosis without increasing the risk of hematologic 
transformation which could be caused by exposure to cytotoxic drugs. On the other hand, 
survival is significantly reduced in primary myelofibrosis, and the clinical manifestations may 
be disabling. In the absence of therapies with the potential of curing the disease, a careful 
risk-oriented approach is employed for stratifying patients to the most appropriate, currently 
available, therapeutic options. In this brief review, we will discuss some of the key issues that 
can arise along the clinical course of MPNs and require an integrated, strictly patient-
oriented, approach. 
  
Introduction: The approach to a patient suffering 
from a Philadelphia-chromosome negative, classic 
Myeloproliferative Neoplasm (MPN)1 can be 
mostly of a strict hematological pertinence or can 
require a complex, multidisciplinary approach in 
cases where the disease has an aggressive course or 
presents or evolves with complications (Table 1). 
There are obvious differences in clinical 
presentation that are related to the unique MPN 
entities, the worse being primary myelofibrosis 
(PMF); however, it must be kept in mind that 
protean clinical issues are largely and often 
unpredictably patient-related. However, from a 
clinical point of view, the most challenging 
consideration for the physician is that while the 
overall survival of PV or ET patients may be only 
marginally affected by the disease, survival may 
range from a few months to an excess of a decade in 
PMF patients. The main complications of 
polycythemia vera (PV) and essential
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Table 1. Some of the key issues in the management of MPN patients that require integrated skills. 
Polycythemia Vera / Essential Thrombocythemia Myelofibrosis 
• Prevention of vascular complication  
• Ongoing treatment of prior thrombotic events 
• Control of myeloproliferation  
• Control of splenomegaly 
• Symptomatic control of disease manifestations  
• Treatment of anemia and cytopenias  
• Control of splenomegaly  
• Control of myeloproliferation  
• Prevention of vascular complication 
• Symptomatic control of disease manifestations 
• Palliative therapy versus HSCT 
• Familial forms and discussion of genetic predisposition 
• Pregnancy management and counseling 
• Choice between no therapy, conventional therapy, experimental therapy 
 
thrombocythemia (ET) are cardiovascular in nature 
and constitute the leading cause of death.2 As such, 
they may require counseling of specialists from 
different fields including cardiologists, vascular 
surgeons, gastroenterologists (for the manifestations 
and complications of splancnic vein thromboses), 
radiologists, and experts in anticoagulation 
therapy.3 A young lady with ET who plans to 
become pregnant, or is expected to deliver, poses 
specific problems in antithrombotic treatment 
during pregnancy and in the immediate post-
delivery period, as well as requires careful 
obstetrician management.4 Furthermore, 
opportunity about a myelosuppressive treatment 
before conception and during pregnancy should be 
accurately discussed in case a woman is considered 
at high-risk because of the characteristics of her 
disease or a history of previous abortions. 
Therapeutic decisions regarding massive and 
symptomatic splenomegaly in MF, and more 
infrequently in PV or ET, may involve the 
hematologist, the surgeon, as well the 
radiotherapist.5 Leukemic transformation is 
associated with a very dismal outcome with 
conventional chemotherapeutic approaches because 
of intrinsic characteristics of the disease as well as 
the almost universal presence of comorbidities in 
older patients; therefore, decisions about choice 
between intensive chemotherapy, a smoother 
therapeutic approach, supportive treatment only, as 
well as counseling for the end-of-life decisions or 
hospice treatment need to be taken by discussing 
with the patients, relatives and colleagues from 
different medical specialites.6 Cutaneous 
complications from cytotoxic therapy with 
hydroxyurea (leg ulcers) represent a relatively 
common side effect of therapy and constitute a 
therapeutic dilemma that requires dermatologist’s 
approach, nurse’s care, and eventually additional 
specialists (experts in hyperbaric therapy, 
reconstructive surgeon). Recent improvement in the 
use of hematopoietic stem cell transplantation in 
patients with MF, and the availability of novel 
drugs, that include JAK2 inhibitors,7 inhibitors of 
histone deacethylases8 and possibly others, will 
probably result in a modification of our current 
approach to MPNs in the near future, making the 
management of these disorders even more complex 
but, hopefully, more effective possibly leading to a 
cure.   
In this review we will briefly discuss four issues 
that are: genetic counseling, the management of 
pregnancy in a woman affected by MPN, how to 
face a massively enlarged spleen in myelofibrosis, 
and the criteria for choosing between conventional 
and experimental therapy. 
 
Genetic counseling: MPNs are not hereditary 
disorders, and as such there has been no indication 
until now to refer patients to an expert of human 
genetics. However, the fact that familial forms of 
MPNs, whose existence has been long known, are 
discovered more and more frequently (their rate 
probably being linearly dependent on the accuracy 
the existence of MPNs in the family is searched for 
by the referring hematologist), and recent 
discoveries about JAK2 46/1-GGCC predisposing 
haplotype, combined with the diffusion of these 
information through specialized and non-
specialized web sites or the print, have all increased 
awareness by the patients, especially youngest. So, 
we can expect that the question “..will I transmit the 
disease to my sons?”  is increasingly proffered to 
physician by newly diagnosed MPN patients. At 
this time speaking, MPNs continue to be purely 
acquired disorders, with no evidence of germline 
transmission, no need of genetic counseling, and no 
need, on the hematologist’s side, to suggest testing 
familial members with either simple (automated 
blood cell count) or complex (molecular analysis of 
JAK2 or similar mutations) laboratory approaches. 
It is key to avoid generating unjustified and 
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unethical “mind storms” in the patients and their 
relatives by an inappropriate usage of the novel 
information deriving from our increasing 
knowledge of the molecular complexity of MPNs. 
 
How to manage pregnancy: The opportunity for a 
physician to deal with a pregnant woman is 
definitely more common in ET than in PV due to 
younger age. There is no controlled study 
concerning management strategies, and 
recommendations only reflect experts’ opinions.9,10 
About seventy per cent of 461 pregnancies reported 
in ET women ended with successful live.11 On the 
other hand, the incidence of major maternal 
complications was significantly higher (44%) in the 
18 PV patients included in one single-centre study12 
as compared to ET (about 5%). Interestingly, an 
association of JAK2V617F mutational status with 
greater occurrence of pregnancy complications in 
ET has been described.13 It is key to identify a “at 
high-risk pregnancy”, such as in a woman who had 
history of previous thrombosis or presented severe 
complications during previous pregnancies. The 
latter include 3 or more first-trimester or 1 or more 
third-trimester losses; a previous birth weight less 
than the 5th centile of gestation; development of 
symptoms of pre-eclampsia; intrauterine death or 
stillbirth. In fact,  a “low-risk pregnancy” in ET 
could be managed with observation only a part for 
maintaining hematocrit level lower than 45% in a 
few cases where the physiologic decrease of 
hemoglobin levels does not happen. There is no 
clear indication to support prophylactic low-dose 
aspirin in the absence of microcirculatory 
symptoms in ET,  while all patients with PV should 
receive aspirin during pregnancy until about 1 week 
before planned delivery. However, in absence of 
controlled studies, some authors consider 
appropriate the administration of low-dose aspirin 
even in “low risk” ET. The presence of classic 
cardiovascular risk factors in these patients, such as 
obesity or bed rest, can be a issue for choosing 
LMWH prophylaxis instead of aspirin. The lack of 
obvious correlation between thrombocytosis and 
pregnancy complication makes correction of 
platelet count not  a relevant target for therapy, also 
considering that platelet count often reaches and 
maintains normal levels throughout pregnancy. 
When there is the need to control 
myeloproliferation interferon-alpha is the only drug 
recommended because its lack of teratogenic 
properties. Neither HU nor anagrelide can be used 
during pregnancy. In the absence of any evidence-
based information in the literature, and only as a 
cautionary attitude, we suggest at least a six-month 
period wash-out from either drug in case of planned 
conception; however, it should be stressed that fetal 
abnormalities have been reported only in one out of 
60 pregnancies that were successfully completed 
under HU.12 Low molecular weight heparin 
(LMWH) is recommended after delivery until six 
weeks postpartum to prevent venous 
throemboembolism; eventually, prophylactic 
LMWH could be started 1-2 weeks before expected 
labour and stopped about 12 hours before. Some 
experts also consider the combined use of aspirin 
and LMWH throughout pregnancy and for six 
weeks after delivery in high-risk ET patients and in 
all PV women.10 Thus, the management of 
pregnancy is a MPN woman is a  complex issue that 
requires interactions of the hematologist with the 
couple to counsel about the best approach and to 
reassure the woman about potential risks and 
benefits of no therapy versus therapy; and with the 
gynecologist and obstetrician for an accurate 
follow-up (it should not be undermined that this is 
anyway a “at risk” pregnancy compared to control 
population). We have to reassure the woman who 
wants to become a mother that this is feasible and 
low-risk, and do our best to make her feeling helped 
and safe at any time point during pregnancy and 
delivery.  There are also some grey areas strictly 
connected with the issue of pregnancy in MPNs; 
these concern counseling about hormonal therapy 
for contraception (that should be discourages as 
possible), about the risk of fetal defects in the case 
conception happened whilst on therapy, and finally 
also about the potential risks associated with the use 
of cytotoxic drugs by the father. Unfortunately, 
there is little to no experience at this regard that can 
help making recommendations, so that only 
prudent, individualized and shared approach can be 
employed. 
 
How to face massive splenomegaly in 
myelofibrosis: Splenomegaly can be found in all the 
MPNs, but it is a main complaint of patients with 
myelofibrosis as the manifestation of massive 
extramedullary hematopoiesis that results largely 
from the substitution of hematopoietic tissue with 
reticulin and collagen fibers in the bone marrow. 
Splenomegaly causes local problems (early saxiety, 
manifestations due to local compression on organ 
and vessels) and contributes to systemic symptoms, 
particularly cachexia, and hematological 
abnormalities due to sequestration of red blood 
cells, granulocytes and platelets. An excellent 
critical review of how to manage splenectomy has 
been published recently.5 No conventional drug is 
effective against huge spleen enlargement, although  
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Table 2. Indications and outcome of splenectomy for massive 
splenomegaly in myelofibrosis. Numerical values indicate 
proportion of the patients. From Mesa5. 
Indications 
• Symptoms ascribable to local compression (50%) 
• Refractory, transfusion-dependent anemia (25%) 
• Refractory thrombocytopenia (15%) 
• Portal hyperthension (10%) 
 
Complications of surgery 
• Overall morbidity (30-40%) 
• Hemorrhage (15%) 
• Thrombosis (10-15%) 
• Fatalities (7-10%) 
Improvement rate 
• Symptoms ascribable to local compression: 50% 
• Anemia: 50% 
• Thrombocytopenia: 30% 
• Portal hyperthension: 40% 
Long-term outcome  
• Leukemia: 10-15% 
• Progressive hepatomegaly: 10-15% 
 
hydroxyurea may help in the early phase of disease. 
Splenectomy carries a considerable risk during 
surgery and in the post-surgery phase due to 
vascular complications, hemorrhages, infections, 
and myeloproliferative reactions (Table 2). 
Splenomegaly can also represent a negative 
prognostic factor for patients undergoing 
hematopoietic stem cell transplantation.14 Thus, 
managing massive splenomegaly in myelofibrosis 
requires an integrated experienced team involving 
the referring hematologist, the radiotherapist, the 
surgeon, a physician experienced in managing 
splancnic thrombotic complications after surgery, 
and eventually an hematologist with experience in 
transplanting myelofibrosis patients. But, first of all, 
a comprehensive discussion with the patient of the 
indications, risk and expected benefits and possible 
risks is mandatory. 
 
Choosing between conventional and 
experimental therapies: The management of ET 
and PV has been traditionally problematic because 
of the lack of robust evidence-based management 
guidelines. Factors for identifying high-risk patients 
who deserve a more aggressive treatment have been 
discovered and validated in large clinical studies, 
and novel ones are under strict scrutiny more 
recently.1 The former are represented by older age 
and a previous history of vascular events, the latter 
are the JAK2V617F mutational status or burden and 
leukocytosis. The widely employed drug in high 
risk patients is hydroxyurea in association with anti-
platelet agents; the approach successfully reduces 
(but does not eliminate) the risk of major 
thrombosis, but whether it is able to modify the 
course of disease is questionable. Although the rate 
of leukemia transformation is probably not different 
from control patient populations, use of a cytotoxic 
drug is preferably to avoid in younger patients. 
Also, although the rate of resistance/intolerance to 
hydroxyurea in probably less than10% of all 
patients, in some instances the treatment has to be 
shifted towards other cytotoxic agents, with a 
measurable increase in the risk of leukemic 
transformation. The scenario in therapeutic 
armamentarium for MPNs is dramatically changing 
(Table 3), and in the next few years it will be 
possible that a number of clinical trials will be 
activated hopefully providing new avenues for 
improving the outcome, the quality of life, and 
reducing complications associated with these 
disorders.
 
Table 3. Novel drugs on the pipeline for MPNs. 
Drug class Molecules Main targets / disease References 
JAK2 inhibitors INCB 018424 TG101348 
Splenomegaly, constitutional symptoms (mainly MF, 
potentially PV or ET) 
[15] 
[16] 
Immunomodulating agents Lenalidomide, Pomalidomide Anemia   (MF) 
[17] 
[18] 
Interferons PEG-interferon-a Mainly PV and ET, preliminary data in early MF [19] 
Histone deacethylase inhibitors Givinostat Mainly PV [20] 
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